BioCentury
ARTICLE | Cover Story

BETting on OncoFusion

May 8, 2014 7:00 AM UTC

Medivation Inc. has licensed a portfolio of BET bromodomain inhibitors that could have better efficacy than the company's castration-resistant prostate cancer drug Xtandi enzalutamide and could provide the biotech with a new way to disrupt androgen receptor signaling. The company got the molecules from OncoFusion Therapeutics Inc. on the same day the startup's founders published compelling preclinical data for inhibiting BET in the indication.1

Under the April 23 deal, Medivation will have exclusive, worldwide rights to selected BET inhibitors. In return, OncoFusion is eligible to receive undisclosed up-front payments and milestones plus royalties...